Who is sponsoring NCT03551782?

NCT03551782 is sponsored by Janssen Research & Development, LLC.

What drugs are being tested in NCT03551782?

Interventions in NCT03551782: Cetrelimab 480 mg, Apalutamide 240 mg.

What condition does NCT03551782 study?

NCT03551782 studies Castration-Resistant Prostatic Neoplasms.

Is NCT03551782 still recruiting?

NCT03551782 is currently completed. Last updated 25 February 2022.

Last reviewed 2022-02-25 · How we verify

NCT03551782

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

Completed Phase 1 Last updated 25 February 2022

What this trial tests

Phase 1 trial testing Cetrelimab 480 mg in Castration-Resistant Prostatic Neoplasms in 33 participants. Completed in 11 November 2021.

Timeline

28 June 2018

Primary endpoint
11 November 2021

11 November 2021

Quick facts

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	28 June 2018
Primary completion	11 November 2021
Estimated completion	11 November 2021
Sites	34 locations across Italy, Netherlands, Russia, Belgium, Canada, United States, Spain

Drugs / interventions tested

Cetrelimab 480 mg — full drug profile →
Apalutamide 240 mg — full drug profile →

Conditions studied

Castration-Resistant Prostatic Neoplasms — all drugs for Castration-Resistant Prostatic Neoplasms →

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

18 and older, male only, with Castration-Resistant Prostatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety of the combination of cetrelimab, with apalutamide and to define a population of participants with metastatic castration-resistant prostate cancer (mCRPC) who respond to treatment with the combination of cetrelimab and apalutamide.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Neuroendocrine and Aggressive-Variant Prostate Cancer.
Spetsieris N, Boukovala M, Patsakis G, Alafis I, et al · · 2020 · cited 62× · PMID 33339136 · DOI 10.3390/cancers12123792
Advances in landscape and related therapeutic targets of the prostate tumor microenvironment.
Li D, Xu W, Chang Y, Xiao Y, et al · · 2023 · cited 21× · PMID 37294106 · DOI 10.3724/abbs.2023092
Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?
von Amsberg G, Alsdorf W, Karagiannis P, Coym A, et al · · 2022 · cited 15× · PMID 35269712 · DOI 10.3390/ijms23052569
A Complete Response to Combined Immunotherapy in a Patient with an ATM plus SF3B1 Mutation and a Moderate Tumor Mutational Burden with a High-Grade Treatment-Emergent Neuroendocrine Prostate Cancer: Case Report and Review of the Literature.
Ferreira Bruzzi Porto H, C K Lopes G, B V Bekierman H, Altino De Almeida S, et al · · 2024 · PMID 39474562 · DOI 10.1159/000540573

Verify or expand the search:

Other trials of Cetrelimab 480 mg

Trials testing the same drug.

NCT03431350 — A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer · Phase 2 · active not recruiting

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03551782 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
Last refreshed: 25 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03551782.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing